News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

BioAlliance Pharma Announces Two Key Steps with Its AMEP™ Biotherapy for Metastatic Melanoma


1/23/2012 11:08:35 AM

PARIS--(BUSINESS WIRE)--Regulatory News:

BioAlliance Pharma SA (Paris:BIO)(Euronext Paris - BIO), a company dedicated to specialty and orphan oncology products, today announces two key steps in the development of its AMEP™ biotherapy with the submission to the French drug agency (Afssaps) of a phase I/II clinical trial in the metastatic melanoma and the grant of a European patent covering the product until 2022.

Read at BioSpace.com


comments powered by Disqus
   
Melanoma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES